直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Tips and Tricks for Making the Most of 60 or 80 Pages!

January 08, 2014

Authored and Edited by Rachel L. Emsley

Several recent Board Notices indicate that the PTAB will not tolerate clever attempts to get around the page limits for inter partes review (IPR) and covered business method review (CBM) petitions (60 and 80 pages, respectively). For example, the Board has indicated that footnotes, the listing of counsel (lead/backup), listing of prior art, and listing of grounds for cancellation, and block quotations all must be double spaced. See, e.g., IPR2013-00033, Papers 79, and 84 (Aug. 9 and 30, 2013).

So, what still works? Petitioners have been using fonts with smaller footprints (such as Garamond), turning on kerning, reducing overhead in the header or footer (while still heeding the 1-inch margin requirement), and experimenting with justified text and auto-hyphenation. Others have used “cross references” (such as “see above at claim X”) in the claim charts to avoid repetitive text, and still others have eliminated claim charts entirely (they are not required, see 77 Fed. Reg. 48764) from the petition, including them only as exhibits. As more institution decisions and denials come out, time will tell whether these or other techniques will ultimately succeed.

 

Copyright © 2014 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Conference

Best Practices and Tech in Intellectual Property Conference 2026

May 17, 2026

Tel Aviv

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP